Article Text

other Versions

Anti-inflammatory effect of retinoic acid on experimental autoimmune uveoretinitis
  1. Hiroshi Keino*,
  2. Takayo Watanabe,
  3. Yasuhiko Sato,
  4. Annabelle A Okada, Dr
  1. 1 Kyorin University School of Medicine, Japan
  1. Correspondence to: Hiroshi Keino, Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa Mitaka, Tokyo, 181-8611, Japan; keino{at}


Aims: To determine whether an active metabolite of vitamin A, all-trans retinoic acid (ATRA), reduces inflammation in experimental autoimmune uveoretinitis (EAU).

Methods: Naive CD4+ T cells were activated with anti-CD3, anti-CD28 and TGF-β, in the presence or absence of ATRA. Intracellular expression of Foxp3 and IL-17 in the activated CD4+ T cells was assessed by flow cytometry. C57BL/6 mice were immunized with human interphotoreceptor retinoid binding protein (IRBP) peptide 1-20 (IRBP1-20). ATRA was administered intraperitoneally every other day (0.2 mg/mouse/day) from day 0 to day 21. In vivo-primed draining lymph node cells from vehicle-treated or ATRA-treated mice were stimulated with IRBP1-20 and culture supernatant was harvested for assay of IFN-γ and IL-17 by enzyme linked immunosorbent assay (ELISA).

Results: ATRA synergized with TGF-β to induce Foxp3+ T regulatory cells (Treg) and reciprocally inhibited development of Th17 cells induced by TGF-β and IL-6. ATRA treatment reduced the severity of EAU clinically and IFN-γ and IL-17 production were significantly reduced in ATRA-treated mice.

Conclusion: These findings demonstrate that ATRA treatment ameliorates severity of EAU and reduces the Th1/Th17 responses. ATRA may represent a new therapeutic modality for human refractory uveitis.

Statistics from


    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.